ATP-dependent transport of statins by human and rat MRP2/Mrp2.

[1]  B. Davis,et al.  Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. , 1999, Circulation.

[2]  M. J. García,et al.  Pharmacokinetic interactions of statins. , 2001, Methods and findings in experimental and clinical pharmacology.

[3]  V. Sasseville,et al.  A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.

[4]  H. Yawo,et al.  Pravastatin, an HMG-CoA Reductase Inhibitor, Is Transported by Rat Organic Anion Transporting Polypeptide, oatp2 , 1999, Pharmaceutical Research.

[5]  T. Horie,et al.  FUNCTIONAL ANALYSIS OF DOG MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2) IN COMPARISON WITH RAT MRP2 , 2005, Drug Metabolism and Disposition.

[6]  P. Neuvonen,et al.  Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics , 2006, Pharmacogenetics and genomics.

[7]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[8]  Paul D. Martin,et al.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.

[9]  Y. Sugiyama,et al.  Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[10]  Balázs Sarkadi,et al.  The role of multidrug transporters in drug availability, metabolism and toxicity. , 2003, Toxicology letters.

[11]  Y. Sugiyama,et al.  A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[12]  J. Xu,et al.  DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.

[13]  M. Yamazaki,et al.  Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. , 1996, Biopharmaceutics & drug disposition.

[14]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[15]  Y. Sugiyama,et al.  Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  K. Kajinami,et al.  Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. , 2006, Cardiovascular drug reviews.

[17]  M. Niemi,et al.  Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans , 2007, Pharmaceutical Research.

[18]  P. Neuvonen,et al.  Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapeutics.

[19]  J. Schellens,et al.  Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)* , 2003, Journal of Biological Chemistry.

[20]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[21]  M. Pfeffer,et al.  Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. , 1998, Journal of the American College of Cardiology.

[22]  S. Grimm,et al.  ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN , 2006, Drug Metabolism and Disposition.

[23]  P. Jansen,et al.  Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Yi Wang,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[25]  N. Kaplowitz,et al.  Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. , 1992, The Journal of biological chemistry.

[26]  J. Turgeon,et al.  Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. , 1998, Trends in pharmacological sciences.

[27]  Aleksandra Galetin,et al.  Multiple Inhibition Mechanisms and Prediction of Drug–Drug Interactions: Status of Metabolism and Transporter Models as Exemplified by Gemfibrozil–Drug Interactions , 2008, Pharmaceutical Research.

[28]  M. Emery,et al.  Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids. , 2004, Bioorganic & medicinal chemistry letters.

[29]  K. Maeda,et al.  DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.

[30]  Y. Sugiyama,et al.  Uptake Is the Rate-limiting Step in the Overall Hepatic Elimination of Pravastatin at Steady-state in Rats , 1996, Pharmaceutical Research.

[31]  K. Maeda,et al.  Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin , 2005, Journal of Pharmacology and Experimental Therapeutics.

[32]  M. Chapman,et al.  Optimizing the pharmacology of statins: characteristics of rosuvastatin. , 2002, Atherosclerosis. Supplements.

[33]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[35]  F. McTaggart.  Comparative pharmacology of rosuvastatin. , 2003, Atherosclerosis. Supplements.

[36]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[37]  A. Peyer,et al.  HMG‐CoA reductase inhibitors and P‐glycoprotein modulation , 2001, British journal of pharmacology.

[38]  J. Staffa,et al.  Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy , 2004, Pharmacoepidemiology and drug safety.

[39]  Thierry Lavé,et al.  New strategies to address drug-drug interactions involving OATPs. , 2007, Current opinion in drug discovery & development.

[40]  F. Russel,et al.  Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. , 2005, American journal of physiology. Renal physiology.

[41]  R. Weaver,et al.  Nonclinical Pharmacokinetics and Toxicokinetics , 2009 .

[42]  R. Sarangapani,et al.  On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[43]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[45]  Leslie Z. Benet,et al.  PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM , 2006, Drug Metabolism and Disposition.

[46]  F. Bernini,et al.  New insights into the pharmacodynamic and pharmacokinetic properties of statins. , 1999, Pharmacology & therapeutics.

[47]  G. Thorgeirsson,et al.  Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. , 1996, Circulation.

[48]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.